TP53 Mutations in AML Patients Are Associated with Dismal Clinical Outcome Irrespective of Frontline Induction Regimen and Allogeneic Hematopoietic Cell Transplantation
<i>TP53</i> mutations are associated with extremely poor outcomes in acute myeloid leukemia (AML). The outcomes of patients with <i>TP53</i>-mutated (<i>TP53</i><sup>MUT</sup>) AML after different frontline treatment modalities are not well established...
Main Authors: | Davidson Zhao, Mojgan Zarif, Qianghua Zhou, José-Mario Capo-Chichi, Andre Schuh, Mark D. Minden, Eshetu G. Atenafu, Rajat Kumar, Hong Chang |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-06-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/12/3210 |
Similar Items
-
Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
by: Davidson Zhao, et al.
Published: (2023-03-01) -
Maintenance therapy for AML after allogeneic HCT
by: Rahul K. Nayak, et al.
Published: (2022-08-01) -
Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease Course
by: Kim L. Clar, et al.
Published: (2021-12-01) -
Bridging Strategies to Allogeneic Transplant for Older AML Patients
by: Judith Hecker, et al.
Published: (2018-07-01) -
Single cell proteogenomic sequencing identifies a relapse‐fated AML subclone carrying FLT3‐ITD with CN‐LOH at chr13q
by: TaeHyung Kim, et al.
Published: (2022-05-01)